Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Renato Vimercati is active.

Publication


Featured researches published by Renato Vimercati.


Journal of Clinical Oncology | 1998

VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.

Gino Santini; L Salvagno; P. Leoni; T. Chisesi; C. De Souza; Mario Roberto Sertoli; Alessandra Rubagotti; A. M. Congiu; R. Centurioni; A. Olivieri; L. Tedeschi; M Vespignani; Sandro Nati; Monica Soracco; A. Porcellini; A Contu; C Guarnaccia; N Pescosta; I. Majolino; Mauro Spriano; Renato Vimercati; Edoardo Rossi; G Zambaldi; L Mangoni; V. Rizzoli

PURPOSE The aim of this multicenter randomized study was to compare conventional therapy with conventional plus high-dose therapy (HDT) and autologous bone marrow transplantation (ABMT) as front-line treatment for poor-prognosis non-Hodgkins lymphoma (NHL). PATIENTS AND METHODS Between October 1991 and June 1995, 124 patients, aged 15 to 60 years, with diffuse intermediate- to high-grade NHL (Working Formulation criteria), stages II bulky (> or = 10 cm), III, or IV were enrolled. Sixty-one patients were randomized to receive etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (VACOP-B) for 12 weeks and cisplatin, cytarabine, and dexamethasone (DHAP) as a salvage regimen (arm A), and 63 to receive VACOP-B for 12 weeks plus HDT and ABMT (Arm B). RESULTS There was no significant difference in terms of complete remissions (CRS) in the two groups: 75% in arm A, and 73% in arm B. The median follow-up observation time was 42 months. The 6-year survival probability was 65% in both arms. There was no difference in disease-free survival (DFS) or progression-free survival (PFS) between the two groups. DFS was 60% and 80% (P = .1) and PFS was 48% and 60% (P = .4) for arms A and B, respectively. Procedure feasibility was the major problem. In arm B, 29% of enrolled patients did not undergo HDT and ABMT. A statistical improvement in terms of DFS (P = .008) and a favorable trend in terms of PFS (P = .08) for intermediate-/high- plus high-risk group patients assigned to HDT and ABMT was observed. CONCLUSION In this study, conventional chemotherapy followed by HDT and ABMT as front-line therapy seems no more successful than conventional treatment in terms of overall results. However, our results suggest that controlled studies of HDT plus ABMT should be proposed for higher risk patients.


British Journal of Haematology | 1981

Severe Aplastic Anaemia: Correlation of in Vitro Tests with Clinical Response to Immunosuppression in 20 Patients

Bacigalupo A; Marina Podestà; Maria Teresa Van Lint; Renato Vimercati; Raffaella Cerri; E. Rossi; M. Risso; Angelo Michele Carella; G. Santini; Eugenio Damasio; Domenico Giordano; Alberto M. Marmont

Summary. Colony formation in agar (CFU‐c) was studied in 20 patients with severe aplastic anaemia by three different assays: (1) cultures of light density untreated marrow cells; (2) cultures of marrow cells manipulated in order to enhance colony formation (pretreatment with antilymphocytic globulin, ALG, or 6‐methylprednisolone, 6‐MPr, T cell depletion, adherent cell (AC) depletion, depletion of both AC and T cells), and (3) co‐culture of putative suppressor T cells with autologous T‐depleted marrow cells.


Cancer | 1985

4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study

Angelo Michele Carella; Gino Santini; Martinengo M; Domenico Giordano; Sandro Nati; Angela Congiu; Raffaella Cerri; Marco Risso; Eugenio Damasio; Edoardo Rossi; Renato Vimercati; Maria A. Pacciarini; Alberto M. Marmont

Twenty‐five adults with previously treated acute leukemia were treated with 4‐demethoxydaunorubicin (Idarubicin) with a daily dose of 8 mg/m2 for 3 days intravenously. Complete remission was achieved in 3 of 18 patients with acute nonlymphoblastic leukemia (ANLL) and 2 of 6 with lymphoblastic leukemia. Complete remissions were observed in two of eight ANLL patients refractory to cytarabine, anthracycline, and m‐Amsa (amsacrine), indicating a lack of cross‐resistance between these drugs and Idarubicin. The median duration of remission was 8 weeks. The main major toxicity of Idarubicin therapy, severe myelosuppression, cannot be considered a toxic effect because it was desired in this case list. Our preliminary results indicate that Idarubicin has significant activity against refractory adult acute leukemia.


Leukemia & Lymphoma | 1996

Twelve Years Experience with High-Dose Therapy and Autologous Stem Cell Transplantation for High-Risk Hodgkin's Disease Patients in First Remission After MOPP/ABVD Chemotherapy

Angelo Michele Carella; Emma Prencipe; Ester Pungolino; Enrica Lerma; Francesco Frassoni; Edoardo Rossi; Domenico Giordano; D. Occhini; Anna Maria Gatti; Roberta Bruni; Mauro Spriano; Sandro Nati; Daniela Pierluigi; Marina Congiu; Renato Vimercati; Jean Louis Ravetti; Massimo Federico

High-dose therapy followed by autografting can cure patients with aggressive Hodgkins disease (HD) refractory or with early relapse to first-line combination chemotherapy. On the other hand, the eradication of the disease is rarely achieved in heavily pretreated patients. It has been suggested that patients with HD with very high risk characteristics at diagnosis, often relapse despite appropriate therapy with 7-8 drugs combination. Thus it seems to us that such patients are potential candidates for early autografting during first remission. Twelve years ago, we initiated a pilot study to investigate whether patients with very high risk characteristics, would benefit from early autografting. The application of early autografting was compared with our historical group of patients in complete remission after receiving MOPP/ABVD, who had the same negative prognostic characteristics, refused autografting and who did not receive other treatment after achieving complete remission. Among the 22 consecutive patients entered into the pilot study and autografted, 18 are alive and 17 (77%) remain alive in unmaintained remission at a median of 86 months. One patient (4%) died of interstitial pneumonitis in the transplantation group. Only 8/24 (33%) patients, who did not receive an autograft, are currently alive and disease free at a median of 89 months. In conclusion, the early application of autografting appears to improve the outcome in patients with very high risk HD who achieved remission with MOPP/ABVD.


European Journal of Haematology | 2009

First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease

Marino Clavio; Maurizio Miglino; Mauro Spriano; Daniela Pietrasanta; Emanuela Vallebella; L. Celesti; L. Canepa; Ivana Pierri; Marina Cavaliere; Filippo Ballerini; Germana Beltrami; Edoardo Rossi; Renato Vimercati; Roberta Bruni; M. Congiu; Sandro Nati; Eugenio Damasio; Gino Santini; Marco Gobbi

Abstract: Fludarabine (25 mg/m2 for 5 d, every 4 wk, for 6 courses) was administered as first line therapy in 32 symptomatic chronic lymphoproliferative diseases. All CLL patients achieved at least partial response (5 CR, 2 nPR, 9 PR) but 44% of patients relapsed. In LG‐NHLs response and relapse rate were similar. Haematological toxicity was low. VDJ rearrangement PCR analysis was performed on marrow samples at diagnosis and at the time of response evaluation. In the 3 patients who underwent high dose therapy with peripheral blood progenitor cell rescue analysis was also performed on apheresis samples and on marrow samples at the end of the procedure. Clonal VDJ rearrangement was always evident after Fludarabine therapy even in those patients who achieved histological and immunophenotypic complete remission, whereas it disappeared in 2 of 3 patients who underwent HDT. Our data confirm that Fludarabine monotherapy can reduce the neoplastic mass to a subclinical level and suggest the possibility that high dose therapy might produce true complete remission.


Acta Haematologica | 1979

Bone Marrow Transplantation for Severe Aplastic Anemia

Alberto M. Marmont; M. T. Van Lint; G. Avanzi; G. Reali; R. Adami; A. Soldá; Paolo Strada; M. Barbanti; Maria Cristina Mingari; O. Soro; G. Grazi; D. Pedullá; Raffaella Cerri; Edoardo Rossi; Domenico Giordano; Gino Santini; Angelo Michele Carella; Marco Risso; Renato Vimercati; Giovanna Piaggio; M. R. Raffo; E. Librace; V. Vitale; Bacigalupo A

9 patients with severe aplastic anemia (SAA) were treated with bone marrow transplantation (BMT). 5 were conditioned with cyclophosphamide and received and HLA-identical graft (4 patients) or a mismat


Leukemia & Lymphoma | 1999

High-dose cyclophosphamide followed by autografting can improve the outcome of relapsed or resistant non-Hodgkin's lymphomas with involved or hypoplastic bone marrow.

Gino Santini; Carmino Antonio de Souza; A. M. Congiu; Sandro Nati; G. Marino; Monica Soracco; Sertoli Mr; Alessandra Rubagotti; Mauro Spriano; Franca Vassallo; Edoardo Rossi; Renato Vimercati; Giovanna Piaggio; Osvaldo Figari; Federica Benvenuto; Monica Abate; Mauro Truini; Jean Louis Ravetti; Iole Ribizzi; Eugenio Damasio

We report our experience of high-dose cyclophosphamide (HDCY) followed by high-dose therapy (HDT) and peripheral blood progenitor cell (PBPC) autografting in patients with diffuse, intermediate and high-grade non-Hodgkins lymphomas who have failed conventional treatment. From 1991 to 1996, 54 consecutive patients pre-treated with a median of two chemotherapy lines entered the study. Eighteen patients (33%) were still responders to conventional chemotherapy (sensitive relapse), and 20 patients (37%) were in partial response (PR) after chemotherapy (CT). Sixteen patients (30%) were resistant to conventional CT either at presentation (non responder) or in relapse (resistant relapse). Thirty-nine patients had bone marrow involved by disease and fifteen had an hypoplastic marrow following conventional treatment. Patients received HDCY (7gr/m2) and G-CSF or GM-CSF in order to collect PBPC. Median collected CD34+ cells was 12.3 x 10(6)/Kg (range 0.7-197). After HDT (BEAM or Melphalan + TBI) 50 patients underwent PBPC autografting. According to intention to treat, 44 (81%) of 54 patients achieved complete remission (CR) (50% after HDCY and 31% after HDT). Procedure related death occurred in 6 patients (11%), one after HDCY and 5 after autografting. Twenty-nine (66%) of 44 patients are still in CR, 7 to 63 months (median 27 months) after the procedure. Three-year probability of survival, disease-free survival and progression-free survival are 63%, 64% and 52% respectively. In conclusion, HDCY is an effective procedure not only in mobilizing PBPC, but also in reducing tumour burden. HDT with PBPC support may further improve the outcome in this category of high-risk non-Hodgkins lymphomas.


Leukemia & Lymphoma | 1991

Autologous Unpurged Bone Marrow Transplantation for Acute Non Lymphoblastic Leukemia in First Remission

Angelo Michele Carella; Sandro Nati; Paolo Carlier; Daniela Pierluigi; Domenico Giordano; Angela Congiu; Gino Santini; Daniele Scarpati; Salvina Barra; Renzo Corvò; Vito Vitale; M. R. Raffo; Raffaella Cerri; Marco Risso; Mauro Spriano; Renato Vimercati; Ester Pungolino; Andrea Bacigalupo; Eugenio Damasio

Forty consecutive adult patients under the age of 50 with acute non-lymphoblastic leukemia (ANLL) in first complete remission, underwent autologous bone marrow transplantation (ABMT) between March 1984 and April 1990. The conditioning regimen employed included cyclophosphamide and total body irradiation, followed by the administration of unpurged ABMT. The median time from diagnosis to transplant was 7 months (3-15 months), and the median time from complete remission to ABMT was 4 months (range 3-9 months). Twenty-two (51%) patients remain in complete remission 6-81 months (median 24 months) after ABMT. The causes of death were, recurrent leukemia (11 patients), parenchymal toxicities such as acute respiratory distress syndrome and veno-occlusive disease (3 patients), hemorrhage (2 patients) and infection (2 patients). Eleven patients relapsed after 3-12 months (median 5 months). This study has produced survival data comparable to those of other institutions employing TBI for either allo or autotransplants.


British Journal of Haematology | 1982

GM-CFC growth in chronic granulocytic leukaemia is not affected by a soluble inhibitor released by aplastic anaemia T-cells or mitogen-primed normal T-lymphocytes

Francesco Frassoni; Marina Podestà; Maria Teresa Van Lint; ALlberto Marmont; Edoardo Roosi; Renato Vimercati; Andrea Bacigalupo

Peripheral blood (PB) and bone marrow (BM) cells were obtained from 12 patients with chronic granulocytic leukaemia (CGL) and cultured in agar for granulocyte macrophage colony formation (GM‐CFC). In addition PB and BM CGL cells were co‐cultured with T‐lymphocytes from patients with immune severe aplastic anaemia (SAA), or with T‐cells from healthy donors primed with pokeweed mitogen (PWM). The supernatants of SAA and PWM primed T‐cells were also added to CGL cells grown in agar. Normal marrow cells obtained from eight healthy donors were used to set up control cultures and co‐cultures. The results of this study indicate that, firstly, T‐cells derived from SAA patients and their supernatants suppress GM‐CFC growth of normal marrow cells but not of PB nor BM CGL cells, and, secondly, normal T‐cells primed with PWM and their supernatants suppress normal marrow GM‐CFC but not colony formation of BM nor PB CGL cells. These results provide further evidence that mediators which are effective in regulating normal myeloid progenitor cells fail to inhibit the in vitro growth of GM‐CFC from CGL patients.


Annals of Oncology | 2005

Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG

A. Olivieri; Gino Santini; Caterina Patti; Teodoro Chisesi; C.C. de Souza; Alessandra Rubagotti; S. Aversa; A. Billio; A. Porcellini; M. Candela; R. Centurioni; A. M. Congiu; M. Brunori; Sandro Nati; Mauro Spriano; Renato Vimercati; G. Marino; A Contu; L. Tedeschi; I. Majolino; Monica Crugnola; Mario Roberto Sertoli

Collaboration


Dive into the Renato Vimercati's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Angelo Michele Carella

Casa Sollievo della Sofferenza

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Raffaella Cerri

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge